Alpha Tau Medical Ltd.

DRTS

IL0011839383

Investment Holding Companies

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
2.43 ^USD	-2.80%		-2.80%	-19.27%

Mar. 07	Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	CI

Alpha Tau Medical Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023

November 16, 2023 at 04:32 pm EST

Alpha Tau Medical Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported net loss was USD 21.79 million compared to USD 30.37 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.49 a year ago.

Latest news about Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	Nov. 28	CI
Alpha Tau, HekaBio Seek Japan's Premarket Approval of Alpha-Radiation Therapy for Head, Neck Cancer	Nov. 20	MT
Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer	Nov. 20	CI
Piper Sandler Adjusts Alpha Tau Medical's Price Target to $8 From $12, Keeps Overweight Rating	Nov. 17	MT
Alpha Tau Medical Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 16	CI
Alpha Tau Medical Ltd. Announces Stephen M. Hahn Joins Scientific Advisory Board	23-10-24	CI
Alpha Tau Medical Treats First Patient With Advanced Inoperable Pancreatic Cancer in Israel Clinical Trial	23-09-14	MT
Alpha Tau Medical Ltd. Treats First Patient with Advanced Inoperable Pancreatic Cancer At Israel's Hadassah Medical Center	23-09-14	CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Alpha Tau Medical Says Alpha DaRT Shows Long-Term Safety, Tumor Control Outcomes for Cancer Patients From Multiple Trials	23-08-18	MT
Traders on Edge Amid Elevated Bond Yields, Driving Premarket Losses for US Equity Futures	23-08-18	MT
Top Premarket Gainers	23-08-18	MT
Alpha Tau Medical Ltd. Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT	23-08-17	CI
Alpha Tau Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Alpha Tau Medical Ltd. Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University	23-05-17	CI
HC Wainwright Starts Alpha Tau Medical at Buy With $9 Price Target	23-04-24	MT
Alpha Tau Medical Ltd. and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial	23-04-03	CI
Alpha Tau Medical Confirms No Direct Exposure To Silicon Valley Bank	23-03-12	RE
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Alpha Tau Medical Ltd. Announces Alpha DaRT Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer Trial	23-03-08	CI
Alpha Tau Medical Granted Amended Radioactive License by Israeli Government	23-03-03	MT
Alpha Tau Medical Ltd. Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters	23-03-03	CI
Alpha Tau Medical Ltd. Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters	23-03-03	CI

Chart Alpha Tau Medical Ltd.

Duration

Period

More charts

Company Profile

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

Sector

Investment Holding Companies

Calendar

2024-05-21 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.43 USD

Average target price

9.25 USD

Spread / Average Target

+280.66%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Shell Companies

	1st Jan change	Capi.
ALPHA TAU MEDICAL LTD.	-19.27%	174M
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+158.06%	6.83B
SCREAMING EAGLE ACQUISITION CORP.	+0.47%	1.01B
CHURCHILL CAPITAL CORP VII	+2.10%	982M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+22.89%	797M
ARES ACQUISITION CORPORATION II	+1.63%	664M
E7 GROUP	-1.80%	617M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ALTC ACQUISITION CORP.	+32.01%	592M

Shell Companies